Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights …,

“We are pleased with the encouraging dose escalation safety and anti-tumor activity data from our Phase 1 clinical trial for STRO-002, including data …, “We are pleased with the encouraging dose escalation safety and anti-tumor activity data from our Phase 1 clinical trial for STRO-002, including data …, Read More

Scroll to Top